Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Evaxion Biotech AS(EVAX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for EVAX
10/09/2026: EVAX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Evaxion Biotech is a clinical-stage company using artificial intelligence to discover cancer and infectious disease vaccines. Its primary strength lies in its proprietary PIONEER and EDEN AI platforms, which aim to streamline the drug development process. The company’s growth story hinges on successfully moving candidates like EVX-01 through clinical trials and securing high-value partnerships. However, investors face substantial risks, including the absence of commercial revenue, high cash burn, and the inherent uncertainty of clinical trial success. The stock is best suited for speculative growth investors who can tolerate high volatility and should focus on monitoring upcoming clinical data and new partnership announcements.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Investors looking for high-risk, high-reward exposure to AI-driven biotech may find potential here, though the path to commercialization is long. |
| Momentum investor | Mixed fit | This is a conditional fit depending on positive clinical trial news or partnership announcements driving short-term interest. |
| Value investor | Weak fit | As a pre-revenue clinical-stage company, traditional valuation metrics like P/E ratios are not applicable. |
| Dividend investor | Weak fit | The company is not currently profitable and does not pay dividends. |
| Low-risk investor | Weak fit | The high volatility and clinical risk make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is highly sensitive to clinical trial results and overall market sentiment for biotech. |
| Valuation risk | High | Valuations for pre-revenue companies are highly subjective and prone to significant corrections. |
| Competition risk (AI-driven biotech) | Medium / high | Well-funded competitors are also utilizing AI to accelerate drug discovery, challenging Evaxion's technological moat. |
| Business quality | Medium | The company relies on its intellectual property and AI engine, which are not yet proven by commercial success. |
| Dividend income | Low / none | There is no income generation for shareholders. |
| Execution risk | High | Failure to achieve positive clinical endpoints for candidates like EVX-01 could severely impact the company's future. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -20.15% | Avg. Invested days 21 | Today’s Advisory WEAK BUY |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/09/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 27.52M USD | Price to earnings Ratio - | 1Y Target Price 11.25 |
Price to earnings Ratio - | 1Y Target Price 11.25 | ||
Volume (30-day avg) 47.6K shares | Beta 0.51 | 52 Weeks Range 2.77 - 12.15 | Updated Date 10/09/2026 |
52 Weeks Range 2.77 - 12.15 | Updated Date 10/09/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Research and Development Partnerships | Collaborations with major pharmaceutical firms to use its AI platforms for drug discovery. | The company primarily generates revenue through strategic partnerships and milestone payments rather than selling commercial drugs. |
Valuation
Trailing PE - | Forward PE 3.57 | Enterprise Value 22.70M | Price to Sales(TTM) 3.67 |
Enterprise Value 22.70M | Price to Sales(TTM) 3.67 | ||
Enterprise Value to Revenue 3.03 | Enterprise Value to EBITDA -0.59 | Shares Outstanding 9.02M | Shares Floating 5.68M |
Shares Outstanding 9.02M | Shares Floating 5.68M | ||
Percent Insiders 16.15 | Percent Institutions 9.42 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.